Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRAZAMINE is a combination product consisting of trazodone hydrochloride, a serotonin antagonist and reuptake inhibitor (SARI), and choline, a precursor to the neurotransmitter acetylcholine. Marketed as a kit by Physician Therapeutics LLC, the product typically contains 50mg trazodone hydrochloride tablets alongside choline supplementation. Trazodone functions as a small molecule antidepressant by selectively inhibiting serotonin uptake and antagonizing 5-HT2 receptors, and it is primarily indicated for major depressive disorder (MDD) and associated anxiety. The addition of choline is intended to support neurotransmitter synthesis, although this specific combination has not been approved by the FDA as safe or effective and is marketed as an unapproved drug product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on choline + trazodone.